Search

everythinglearnresearchcommunity

for

Search:↓

The post is about a user's progress with using minoxidil and finasteride for hair loss. One user suggests that dermarolling may also be contributing to the positive results.

Microneedling can be followed by using Minoxidil, finasteride, or RU58841. Topical caffeine is also an option.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

The conversation is a satirical discussion about using a dermaroller on the penis, with mentions of adding finasteride and doing exercises like cock pushups and planks. Some users joke about side effects and the absurdity of the topic.

A 57-year-old man shared his 6-month hair regrowth progress using RU58841, Minoxidil, microneedling, and Nizoral. He experienced significant improvement, with a smaller bald spot, thicker hair, and hairline regrowth.

The conversation is about hair loss treatments, specifically discussing the use of Minoxidil, Finasteride, and RU58841. A user inquired about the availability of Winlevi (clascoterone) for hair loss.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

The user experienced increased hair shedding after using RU58841, despite initial improvements in scalp condition and appearance. They are considering stopping RU58841 to see if shedding decreases.

Pyrilutamide from RUdirect is discussed, with users sharing experiences and alternative sources like Koshinemall. Users mention using treatments like minoxidil, RU58841, and dutasteride for hair loss.

The user has been using topical finasteride 0.1%, minoxidil 5%, red light therapy, a multi-peptide serum, and a weekly oil hair mask with various oils for hair loss treatment. They also use ketoconazole shampoo, condition their hair, and microneedle with a dermapen.

HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.

The user discussed switching from RU58841 with Minoxidil to Finasteride due to cost, noting better physical feelings and hair growth with RU58841. They are considering returning to RU58841 and checking DHT levels after a month.

The user is starting a new hair loss treatment routine with Minoxidil, Redensyl, Ketoconazole shampoo, and microneedling. They are avoiding finasteride due to potential side effects and are considering future treatments like pyrilutamide.

A 19-year-old with rapid hair loss since 16 is considering a hair transplant but refuses to take finasteride or any 5α-Reductase inhibitors. They are currently using minoxidil, tretinoin, and microneedling with a Derminator 2, and only want hair until age 27.

User experienced scarring from microneedling at fast speed and paused treatment for 3-4 weeks to recover. Advice given includes waiting a full month for recovery to avoid scars.

The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.

OP mixed RU58841 with minoxidil and noticed undissolved particles. They are seeking advice on whether it matters or how to fully dissolve it.

The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.

The conversation discusses using RU58841 at a 2% concentration as an alternative due to side effects from finasteride. The user plans to start with a lower concentration and increase if necessary.

A user shared their initial experiences with The Ordinary hair density serum, which contains Redensyl (taxifolin). They observed increased hair volume but also developed pimples, likely due to the serum stimulating sebaceous glands.

The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.

The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

Users discuss using RU58841 with finasteride, dutasteride, and minoxidil for hair loss, noting reduced itching and effective results. Some users report no side effects, while others experience side effects with dutasteride.

The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.

The user experienced side effects from daily 1 mg Finasteride and switched to 0.5 mg every other day, supplemented with creatine, tongkat ali, tribulus terrestris, vitamin D3, bromantane, l-tyrosine, and caffeine. They also use weekly 1.5 mm microneedling and daily 50 mg RU58841, except on microneedling days, to manage hair loss.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

User starts Nuclear Stack treatment for hair loss, including Dutasteride, Minoxidil, RU58841, Derminator 2, and supplements. Seeks advice on storing and dosing RU58841.

The conversation discusses hair regrowth using dissolvable microneedles loaded with rapamycin and epigallocatechin gallate nanoparticles. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses using RU58841, Minoxidil, and finasteride for hair loss treatment. It focuses on homebrewing RU58841 while using other treatments.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.